Adjuvant Exemestane Therapy After 5 Years of Tamoxifen: Rationale for the NSABP B-33 Trial
May 1st 2001Tamoxifen (Nolvadex) has long been established as "standard" adjuvant therapy for receptor-positive, early-stage breast cancer. Results from clinical trials suggest that after approximately 5 years, tamoxifen may lose its
UFT/Leucovorin vs 5-FU/Leucovorin in Colon Cancer
October 1st 2000Adjuvant chemotherapy has been shown to alter the natural history of resected colon cancer. Two regimens (fluorouracil [5-FU] plus leucovorin and 5-FU plus levamisole) have been found to prolong disease-free survival and overall survival in affected patients.
Preoperative Doxorubicin Plus Cyclophosphamide Followed by Preoperative or Postoperative Docetaxel
June 1st 1997Protocol B-27, conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), is a phase III, randomized trial designed to evaluate whether sequencing docetaxel (Taxotere) to neoadjuvant doxorubicin/cyclophosphamide (Cytoxan, Neosar) prolongs disease-free and overall survival in patients with operable breast cancer.